Reyad Dada
YOU?
Author Swipe
View article: Redefining Precision Management of r/r Large B-Cell Lymphoma: Novel Antibodies Take on CART and BMT in the Quest for Future Treatment Strategies
Redefining Precision Management of r/r Large B-Cell Lymphoma: Novel Antibodies Take on CART and BMT in the Quest for Future Treatment Strategies Open
The treatment paradigms for patients with relapsed large B-cell lymphoma are expanding. Chimeric antigen receptor technology (CAR-T) has revolutionized the management of these patients. Novel bispecific antibodies and antibody–drug conjuga…
View article: Scoring System for Patients with Cancer to Weigh Risk/Benefit of Chemotherapy During Outbreak of COVID-19
Scoring System for Patients with Cancer to Weigh Risk/Benefit of Chemotherapy During Outbreak of COVID-19 Open
Coronavirus disease 2019 (COVID-19) is impacting our daily practice. Hematologist and oncologist around the globe are concerned and many physicians are hesitating to start/continue antineoplastic treatment in patients with cancer to protec…
View article: Saudi lymphoma group's clinical practice guidelines for diagnosis, management and follow-up of patients with various types of lymphoma during the Coronavirus Disease 2019 pandemic
Saudi lymphoma group's clinical practice guidelines for diagnosis, management and follow-up of patients with various types of lymphoma during the Coronavirus Disease 2019 pandemic Open
The Saudi Lymphoma Group had previously published recommendations on the management of the major subtypes of lymphoma. However, the effect the currently ongoing coronavirus disease 2019 (COVID-19) pandemic has on the management of patients…
View article: The AUGMENT study
The AUGMENT study Open
Follicular lymphoma is the most common form of indolent Non-Hodgkin Lymphoma and characterized by repeated relapses. Follicular lymphoma (FL) tissue was found to have association between malignant cells and benign immune cells represented …
View article: Hodgkin’s Lymphoma: Saudi Lymphoma Group’s Clinical Practice Guidelines for Diagnosis, Management and Follow-up
Hodgkin’s Lymphoma: Saudi Lymphoma Group’s Clinical Practice Guidelines for Diagnosis, Management and Follow-up Open
Guidelines 1. DIAGNOSIS AND WORK-UP 1.1.The diagnostic work up for HL patients has evolved since the introduction of positron emission tomography-computed tomography (PET/CT) scanning.In patients undergoing PET/CT evaluation, a bone marrow…
View article: Diagnosis and management of follicular lymphoma: A comprehensive review
Diagnosis and management of follicular lymphoma: A comprehensive review Open
Follicular Lymphoma (FL) is an indolent lymphoma and may have various clinical courses. Worldwide, FL is the second most common non‐Hodgkin lymphoma (NHL) type after diffuse large B‐cell lymphoma. In this review article, the author is disc…
View article: From Diagnosis to Survivorship: Using Cancer Support Group as an Advocacy and Support Platform for Cancer Care in Nigeria
From Diagnosis to Survivorship: Using Cancer Support Group as an Advocacy and Support Platform for Cancer Care in Nigeria Open
Background and context: Cancer diagnosis comes with a lot of challenges. It is a huge burden to the patient, family, and community; subjecting them to financial crisis, emotional distress, dearth of self-esteem, and physiologic deformation…
View article: Neoadjuvant Chemotherapy With Capecitabine Plus Cisplatin in Patients With Locally Advanced Nasopharyngeal Cancer: Case Series Study
Neoadjuvant Chemotherapy With Capecitabine Plus Cisplatin in Patients With Locally Advanced Nasopharyngeal Cancer: Case Series Study Open
Purpose Capecitabine, an oral fluorouracil (5-FU) derivative, has replaced 5-FU in many chemotherapy regimens used in various GI tract cancers. The experience with capecitabine in nasopharyngeal carcinoma (NPC) is limited. Patients and Met…
View article: Time from last chemotherapy to death and its correlation with the end of life care in a referral hospital
Time from last chemotherapy to death and its correlation with the end of life care in a referral hospital Open
Background: A substantial number of cancer patients receive chemotherapy until the end of life (EoL). Various factors have been shown to be associated with receipt of chemotherapy until near death. In this study, we determine our average t…